KDM1A and cancer: LSD1 blockade with the small molecule inhibitor CBB1007 has been shown to enhance repressive H3K9 methylation at the stemness-specific enhancer of SOX2, thereby validating the notion that LSD1 might serve as a selective epigenetic target for therapeutic ablation of SOX2-driven cancer stemness [15].